Novartis ₹1,250 Crore Acquisition: Why Is The Pharma Giant Betting Big On Minipress XL?

Novartis is making a strategic move in India’s fast-growing cardiology segment with the acquisition of Minipress XL for around ₹1,250 crore. The brand generated ₹228.6 crore in revenue over the last 12 months, raising questions about the valuation and long-term potential of the deal. Buisness Today’s Neetu Chandra Sharma explains the strategic rationale behind the acquisition, including the brand’s established prescription base, prescriber loyalty and growth potential. Novartis is effectively paying around 5.5 times annual sales, making this a significant bet on an established revenue-generating asset rather than building a product from scratch. Watch the full analysis of Novartis’ latest pharma acquisition.